Skip to main content

    Main navigation

    • Investors
    • About
    • News
    • Contact us
    • Egoo.health
    • en
    • sv
Home

Main navigation

  • Investors
  • About
  • News
  • Contact us
  • Egoo.health
  • en
  • sv
 

Investors

+

Main navigation

Main navigation

  • News - Press releases
  • Financial Calendar
  • Financial reports
    • IPO and listning documents
  • Corporate governance
    • Articles Of Association
    • AGM and Extraordinary general meetings
      • Annual General Meeting on May 5 2022
      • Annual general meeting on 5 May 2021
      • Extraordinary Shareholders Meeting 19 November
      • Extraordinary general meeting January 2020
      • Annual General Meeting, May 20, 2020
    • Auditor
    • Nomination Committee
    • Certified adviser
  • Share information
    • Major shareholders
    • Sharecapital
    • Incentive programme
    • Dividend Policy
    • Warrants (TO)
  • Board
  • Management
  • Insiders
  • IR Contact
  • Presentations

Management

Thomas Warthoe

Thomas Warthoe

CEO, CO-FOUNDER

Number of shares: 1 507 053

Entrepreneur with over 20 years of experience in the healthcare industry (and specifically diagnostics). Thomas has founded and developed three biotech companies. In two of the companies Thomas founded, Display System Biotech and Ampligon, successful exits were made. He has successfully entered strategic partnerships and licensing agreements with global diagnostic companies such as Backman Coulter, Shionogi Co and Omron Healthcare over the years.

Employed in Qlife Aps since founding 2018

Peter Warthoe

Peter Warthoe

CSO, CO-FOUNDER

Number of shares: 1 201 200

Peter is an entrepreneur who has co-founded companies in life sciences, diagnostics and technology. Peter is a prominent scientist and has been quoted in a variety of scientific writings and has been mentioned more than a thousand times for his discovery of a gene profiling technique. Peter has made over 10 patent applications. Furthermore, he has an extensive network within and experience from negotiations with global medtech companies. Peter has the overall scientific responsibility for the company's products.

Employed in Qlife Aps since founding 2018

Maiken Worsøe Rosenstierne

DIRECTOR R&D

Maiken is a Biochemist with an MSc and PhD Career: Postdoc at University of Copenhagen and at Roskilde University. Maiken was previously a Senior Scientist at Statens Serum Institut and is a respected scientist and a solid leader of multiple R&D projects and our large R&D department.

Kristina Christensen

DIRECTOR QA/RA

Kristina has extensive experience in IVD and Medical Devices within the areas of Quality Assurance, Design Control, Risk Management, Product Development of reagents and instruments and clinical evaluations.

Kasper Boel Rousøe

CFO

Kasper joined Qlife on March 1, 2022, bringing more than 20 years of experience from leading roles in the financial area. Kasper hold a M. Sc. in Economics from Copenhagen University and an EMBA from IMD in Lausanne, Switzerland.

jakob

Jakob Broberg Lind

GLOBAL SALES DIRECTOR

Lab technician & Bachelor of Science – Copenhagen University

Number of shares: 22 663

Staff warrants: 110 000

Jakob is a Senior Healthcare Executive with +12 years’ experience with business development and strategic sales within medical devices. He brings a solid record of results and success from leading companies like Boston Scientific and Medtronic.
 

John Søndergård

DIRECTOR PRODUCTION

John is a senior executive from the MedTech and Pharma industry with more than 30 years of international management and leadership experience within manufacturing and R&D.

 

         
         
         

Qlife

Qlife Holding AB
Redaregatan 48
SE-252 36 Helsingborg, Sweden
info@egoo.health

Links

  • About
  • Investors
  • Egoo.health

Qlife Holding AB is a med-tech group that strives to revolutionize the market for clinical biomarker and virus tests. By enabling tests at home as a complement to tests in healthcare, access to important health information that can contribute to better treatment and potential prevention of diseases is facilitated. On March 2, 2020, Qlife Holding completed a listing on the Nasdaq First North Growth Market, Stockholm. The company currently has about 40 employees.